NCT05945823 2026-04-09
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Taiho Oncology, Inc.
Phase 2 Active not recruiting
Taiho Oncology, Inc.
Boundless Bio, Inc.
Institut National de la Santé Et de la Recherche Médicale, France